(Q36915520)

17 August 2017

1 reference

title

Electroconvulsive therapy in the treatment-resistant patient (English)

1 reference

17 August 2017

Electroconvulsive Therapy in the Treatment-Resistant Patient (English)

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

19 November 2022

author name string

Devanand DP

1

1 reference

17 August 2017

Sackeim HA

2

1 reference

17 August 2017

Prudic J

3

1 reference

17 August 2017

language of work or name

1 reference

1 December 1991

1 reference

full work available at URL

17 August 2017

https://api.elsevier.com/content/article/PII:S0193953X18302752?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

https://api.elsevier.com/content/article/PII:S0193953X18302752?httpAccept=text/plain

19 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Psychiatric Clinics of North America

19 November 2022

published in

1 reference

17 August 2017

volume

14

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

905-923

1 reference

How long should drug therapy for depression be maintained?

17 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Is unilateral electroconvulsive therapy really the treatment of choice in endogenous depression?

19 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations

19 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

19 November 2022

Convulsion dependence.

10

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Electroconvulsive therapy: results in depressive illness from the Leicestershire trial

19 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Lithium continuation therapy following electroconvulsive therapy

19 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Outcome at Discharge and Six Months in Major Depression

19 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Controlled trials of electroconvulsive therapy

19 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

The management of resistant depression.

19 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.

19 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Continuation ECT in the management of relapses of major affective episodes

19 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders

19 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Three-year outcomes for maintenance therapies in recurrent depression

19 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Electroconvulsive therapy. Indications and contraindications

19 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Prognosis of depression treated by electric convulsion therapy.

19 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

A Seven-Month Double-Blind Trial of Amitriptyline and Diazepam in ECT-Treated Depressed Patients

19 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients

19 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

An evaluation of continuation therapy with tricyclic antidepressants in depressive illness

19 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Delusional unipolar depression: description and drug response

19 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Use of ECT with treatment-resistant depressed patients at the National Institute of Mental Health

19 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Treatment of unipolar depression following electroconvulsive therapy. Relapse rate comparisons between lithium and tricyclics therapies following ECT.

19 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Electroconvulsive therapy as an anticonvulsant. Implications for its mechanism of action in affective illness

19 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression

19 November 2022

41

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Continuation drug therapy for major depressive episodes: how long should it be maintained?

19 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness.

19 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Medication resistance and clinical response to electroconvulsive therapy.

19 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Schizophrenia with good and poor outcome

19 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Duration of antidepressant drug treatment. What is an adequate trial?

19 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Effects of electrode placement on the efficacy of titrated, low-dose ECT

19 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.

19 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Imipramine with electrical treatment in depression--a controlled trial

19 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Delusional Depression and Electroconvulsive Therapy: One Year Later

19 November 2022

56

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

The pharmacological treatment of delusional depression

19 November 2022

57

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Research diagnostic criteria: rationale and reliability

19 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Prophylactic electroshock a five year study

19 November 2022

59

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

Use of ECT in the United States in 1975 and 1980.

19 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30275-2

19 November 2022

Identifiers

1 reference